ondansetron (Zuplenz / ondansetron OFDS)

✓ Approved

什么是 ondansetron？

ondansetron 是一种小分子，由Galena Biopharma, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名	Zuplenz, ondansetron OFDS
公司	Galena Biopharma, Inc.
药物类别	小分子
分子靶点	HTR3A
给药途径	Oral (PO)
状态	Approved

来源： ClinicalTrials.gov, Galena Biopharma, Inc.

作用机制

分子靶点

ondansetron 作用于 1 个分子靶点：

HTR3A

5-hydroxytryptamine receptor 3A (5-HT3R, 5-HT-3)

需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

相关研究文献

PubMedAnesthesia and analgesia2026-09-10

A Double-Blinded Randomized Trial Comparing Dexamethasone to Ondansetron as the First-Line Antiemetic After Cesarean Delivery.

Berger Amnon A AA, Borrelli Maria C MC, Patrocinio Maria M, Armstrong Samantha L SL et al.

Postoperative nausea and vomiting is a common adverse outcome after cesarean delivery. Both ondansetron and dexamethasone are effective prophylactic medications; however, dexamethasone has also been shown to decrease pain medication use after cesarean delivery. We hypothesize that dexamethasone may be preferred as the first-line agent due to the dual benefit of reduced nausea and opioid consumption. Prospective randomized, double-blinded, controlled trial comparing dexamethasone 8 mg to ondansetron 4 mg. Patients received spinal anesthesia including morphine150 µg, and an enhanced recovery after cesarean protocol with scheduled nonopioid analgesic medications. The main outcome was the total number of medications for the treatment of any nausea and vomiting, pain, or pruritus in the first 24 hours following cesarean. One hundred patients were enrolled and 95 completed the trial. We found no difference in the mean (95% confidence interval of the mean) number of postoperative medications (ondansetron 0.23 [0.11-0.35], dexamethasone 0.40 [0.20-0.61] medications per patient per 24 hours; P = .337). Differences in the use of supplemental pain medications and pain scores were not statistically significant over the 24-hour period. Similarly, differences in nausea and pruritus scores were not statistically significant over 24 hours. We found no differences in the number of medications used to treat pain, nausea, or pruritus in the first 24 hours after cesarean delivery between women who received either ondansetron or dexamethasone. We also found no difference in pain despite prior research showing improvement with dexamethasone, which may be due to the low pain scores and rate of breakthrough postoperative pain in our study.

PMID 42721472

阅读全文 →

PubMedCureus2026-09-10

Treating Intractable Nausea and Vomiting in Cerebellar and Medullary Stroke.

Bhatti Adil A, Schultz Peter P, Amin Shantanu S, Khalid Taimur T et al.

Cerebellar and medullary stroke can cause persistent nausea and vomiting that may be resistant to initial antiemetic monotherapy and interfere with oral intake and recovery. Evidence guiding management remains limited. We report a 48-year-old man with diabetes mellitus and acute-to-subacute infarcts involving the inferomedial right cerebellum and posterior right medulla who presented with 10 days of persistent nausea and vomiting accompanied by focal neurologic symptoms. Diabetic gastroparesis was considered, but abdominal imaging and gastric emptying scintigraphy did not support a contributory gastrointestinal cause. Ondansetron and metoclopramide provided only limited or temporary relief. Symptoms improved after sequential escalation to ondansetron, chlorpromazine, prochlorperazine, and amitriptyline; transdermal scopolamine was included in the discharge regimen. Nausea and vomiting were nearly resolved before discharge and fully resolved by three-month follow-up. Because multiple medications were introduced over a short interval and natural neurologic recovery may have contributed, the effect of any individual agent or combination cannot be determined. This case suggests that receptor-diverse pharmacotherapy may be considered when initial treatment fails while underscoring the need for further study of efficacy, safety, and medication sequencing.

PMID 42719464

阅读全文 →

PubMedPediatric emergency care2026-09-07

Effect of Intravenous Pantoprazole on Clinical Outcomes in Pediatric Acute Gastroenteritis: A Placebo-Controlled RCT.

Malekiantaghi Armen A, Babajani Nastaran N, Saeedian Behrad B, Eftekhari Kambiz K

Acute gastroenteritis (AGE) is a common cause of pediatric emergency visits, and vomiting often complicates oral rehydration. Despite lack of evidence, proton pump inhibitors (PPIs) are sometimes used empirically for persistent vomiting. We evaluated the effect of intravenous pantoprazole on clinical outcomes in children with AGE and persistent vomiting after ondansetron. This double-blind, placebo-controlled randomized trial was conducted at Bahrami Children's Hospital, Tehran, Iran Children aged 4 months to 18 years with AGE and persistent vomiting despite ondansetron were randomized to receive intravenous pantoprazole (2 mg/kg/d) or placebo. Primary outcomes were vomiting frequency, time to oral tolerance, and length of hospital stay. Analyses used the Mann-Whitney U test, the Fisher exact test, and the ordinal logistic regression. Of 100 children [51 pantoprazole, 49 placebo; median age 14 months (IQR: 11 to 24), 67% male], there were no significant differences between groups in post-treatment vomiting episodes (P=0.64), time to oral tolerance at 6 hours (71% vs. 79%, P=0.37) or 12 hours (86% vs. 86%, P=0.78). However, hospital length of stay was significantly longer in the pantoprazole group [median 2 days (IQR: 1 to 3) vs. 1 day (IQR: 1 to 2), P=0.01]. Ordinal logistic regression showed that the placebo group had 80% lower odds of prolonged hospitalization (adjusted OR=0.2, 95% CI: 0.09-0.43). Subgroup analyses revealed that this difference was more pronounced in children under 2 years, regardless of reflux history, and in formula-fed children (P=0.01 for each). Intravenous pantoprazole does not reduce vomiting or improve oral tolerance in children with acute gastroenteritis. Furthermore, it is associated with longer hospital stays. Empirical PPI use in this setting is not supported by current evidence.

PMID 42703070

阅读全文 →

PubMedJournal of paediatrics and child health2026-09-04

Primary Care Ondansetron Use and Subsequent Emergency Department Utilization in Children With Acute Gastroenteritis.

Borland Jamar J, Hsieh Michael T MT, Rivera-Sepulveda Andrea A

Evaluate whether outpatient ondansetron prescription or in-office administration during a primary care (PC) visit was associated with subsequent emergency department (ED) utilization and downstream healthcare recourse utilization among children with acute gastroenteritis (AGE). We conducted a retrospective cohort study of children aged 6 months to < 18 years presenting to 39 PC clinics with vomiting, diarrhoea, or AGE between 2017 and 2023. Only the first eligible visit for each child was included. The primary outcome was an ED visit within 7 days of the index PC visit. Secondary outcomes included ED acuity, hospital admission, and ED healthcare resource utilization among children subsequently presenting to the ED. Associations were evaluated using logistic and negative binomial regression models. We included 11 343 unique children. Ondansetron was prescribed during 3789 (33.4%) index PC visits, including 782 (20.6%) children who also received an in-office dose. Overall, 63 children (0.6%) presented to the ED within 7 days. Outpatient ondansetron prescription was not associated with subsequent ED utilization (OR 1.07, 95% CI 0.63-1.78; p = 0.798). Among children subsequently presenting to the ED, prior ondansetron exposure was not associated with ED acuity, hospital admission, or overall healthcare resource utilization, although fewer laboratory tests were performed (IRR 0.45, 95% CI 0.22-0.89; p = 0.026). Outpatient ondansetron prescription during PC visits for paediatric AGE was not associated with reduced ED utilization within 7 days. These findings should not be interpreted as evidence that ondansetron lacks clinical benefit but rather that downstream healthcare utilization is influenced by factors beyond symptom control alone. Ondansetron should continue to be considered an adjunct to oral rehydration therapy in appropriately selected children with AGE.

PMID 42693814

阅读全文 →

PubMedMinerva anestesiologica2026-09-04

Comment on: Preoperative ondansetron lozenge for prevention of postoperative nausea and vomiting in pediatrics undergoing squint surgeries: a randomized controlled trial.

Koç Muhammed N MN, Keklicek Ömer Ö

PMID 42693895

阅读全文 →

PubMedHeart & lung : the journal of critical care2026-09-04

Association of common QT-prolonging medications with arrhythmic risk in patients with bundle branch block: A stratified cohort analysis in left bundle branch block vs. right bundle branch block phenotypes.

Derector Evan E, DO Tirth Patel TP, Watanabe Hiroto H, Solomon Diana D et al.

Bundle branch block (BBB) affects 11-17% of adults over 80 and is associated with mortality and heart failure. Conventional QTc formulae overestimate repolarization in wide QRS complexes, with clinicians holding symptom-management therapies based on inaccurate measurements. This retrospective study utilized the MIMIC-IV database to examine arrhythmogenic risk by drug class and BBB phenotype. Adult ICU admissions with BBB were stratified by drug exposure: amiodarone, high-risk anti-arrhythmics (sotalol, dofetilide, procainamide, ibutilide, quinidine, disopyramide), and common non-cardiac QT-prolonging agents (haloperidol, ondansetron, quetiapine, methadone, levofloxacin, azithromycin). The primary outcome was a composite of ventricular arrhythmia and cardiac arrest; a sensitivity analysis restricted to ventricular arrhythmia was performed. Propensity score matching (1:1) with time-varying Cox regression addressed confounding and immortal time bias. The matched cohort included 1722 admissions (LBBB =1252; RBBB =470). Common non-cardiac agents were not associated with the composite outcome in LBBB (HR 0.96, p = 0.83) or RBBB (HR 0.61, p = 0.24; 28 events, hypothesis-generating). Amiodarone was associated with the composite (LBBB: HR 3.63, p < 0.01; RBBB HR: 3.90, p < 0.01), but not the LBBB sensitivity analysis (HR 1.61, p = 0.19), suggesting confounding by indication. Among patients with QTc >500 ms, common agents remained non-significant. Common non-cardiac QT-prolonging medications were not associated with increased risk in patients with BBB, even with prolonged QTc. The divergence between composite and sensitivity results for amiodarone highlights the influence of confounding by indication. Medication alerts should incorporate stratification by drug class rather than QTc alone.

PMID 42697068

阅读全文 →

注册免费账户还可查看另外 5403 篇文献

免费注册查看全部文献 →

ondansetron (Zuplenz / ondansetron OFDS)

什么是 ondansetron？

药物档案

作用机制

分子靶点

相关研究文献

A Double-Blinded Randomized Trial Comparing Dexamethasone to Ondansetron as the First-Line Antiemetic After Cesarean Delivery.

Treating Intractable Nausea and Vomiting in Cerebellar and Medullary Stroke.

Effect of Intravenous Pantoprazole on Clinical Outcomes in Pediatric Acute Gastroenteritis: A Placebo-Controlled RCT.

Primary Care Ondansetron Use and Subsequent Emergency Department Utilization in Children With Acute Gastroenteritis.

Comment on: Preoperative ondansetron lozenge for prevention of postoperative nausea and vomiting in pediatrics undergoing squint surgeries: a randomized controlled trial.

Association of common QT-prolonging medications with arrhythmic risk in patients with bundle branch block: A stratified cohort analysis in left bundle branch block vs. right bundle branch block phenotypes.

了解更多ondansetron